Stay updated on Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page.

Latest updates to the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page
- CheckyesterdayChange DetectedThe recruitment status changed to not actively recruiting participants, and the record history shows a new software revision (v3.6.0) with the prior revision (v3.5.5) removed.SummaryDifference0.2%

- Check8 days agoChange DetectedThe history now shows Revision: v3.5.5 as the latest entry, replacing the previous Revision: v3.5.4.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe page now shows Revision: v3.5.4, replacing v3.5.3. This indicates a minor platform update to the page.SummaryDifference0.0%

- Check51 days agoChange DetectedThe page’s displayed interface/version label has been updated from “v3.5.0” to “v3.5.3,” indicating a site revision rather than a change to the clinical trial record.SummaryDifference0.0%

- Check87 days agoChange DetectedRevision: v3.5.0 added and Revision: v3.4.3 removed in the study history. This is a minor version-tracking update and does not modify study data or page content.SummaryDifference0.0%

- Check101 days agoChange DetectedAdded Revision: v3.4.3 and removed Revision: v3.4.2 from the history log.SummaryDifference0.0%

Stay in the know with updates to Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page.